Sharps Technology, Inc. — 2023 Form 10-K summary
Filing identity and period: The request metadata names Skyai, Inc., but the supplied filing is for Sharps Technology, Inc. (Nasdaq: STSS; warrants: STSSW), for the fiscal year ended December 31, 2023. This is an annual report; the filing does not provide standalone fourth-quarter results.
Business context
Sharps is a pre-revenue medical-device company developing and commercializing safety syringes and drug-delivery products. Its portfolio includes Securegard, Sologard, and Provensa, and it operates a 41,000-square-foot manufacturing facility in Hungary. The company reported no revenue through year-end 2023, despite beginning commercial production and building inventory.
Financial results and liquidity
- Revenue: $0 in both 2023 and 2022. Gross margin and operating margin are not meaningful because there were no sales.
- Net loss: $9.84 million in 2023 versus $4.64 million in 2022; basic and diluted loss per share was $0.76 versus $0.57.
- Operating expenses: $10.13 million, up from $8.74 million. Research and development fell 30% to $1.61 million; general and administrative expense rose 32% to $8.52 million.
- Notable expense items: 2023 included a $560,000 impairment of molds. G&A increases included higher payroll and consulting, professional fees, depreciation, technology costs, and $375,000 of separation expense for a former officer.
- Cash flow: Cash used in operations was $8.51 million, compared with $6.43 million in 2022. Investing activities used $698,000; financing provided $8.03 million, principally from 2023 offerings.
- Cash and working capital: Year-end cash was $3.01 million, down from $4.17 million. Working capital was $1.15 million, down from $2.42 million. Inventory increased to $1.71 million from $186,000.
- Debt and liabilities: The balance sheet reports no outstanding note payable; the $2 million bridge note was repaid in 2022. Year-end warrant liabilities were $2.42 million, and total liabilities were $3.85 million.
- Equity and financing: Stockholders’ equity was $7.93 million, down from $9.64 million. The company raised approximately $8.03 million net in 2023 and disclosed substantial outstanding warrants and options that could dilute shareholders.
Changes versus 2022
Net loss more than doubled as G&A rose and the prior-year benefit from warrant fair-value changes was much larger. R&D declined as the Hungary facility shifted from development and testing toward manufacturing. Inventory expanded significantly, while cash and working capital declined despite equity financing. The company recorded a $560,000 mold impairment in 2023; no impairment was reported in 2022.
Outlook, commentary, and risks
- Going concern: The auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management said existing cash was insufficient for planned operations over the next 12 months and expects to rely on equity or other financing. The audited statements contain no adjustments for a possible inability to continue as a going concern.
- Commercialization: Management said it was producing commercial quantities and building inventory, and disclosed a purchase order for initial Securegard sales to South America. It did not report recognized revenue. Provensa commercialization remains delayed, with no determinable launch timeline.
- Business agreements: A September 2023 agreement to acquire equipment and leasehold improvements at Nephron’s South Carolina facility remained contingent on obtaining financing. Management described anticipated prefillable-syringe supply beginning in early 2025. In March 2024, Roncadelle became an exclusive distributor for Sharps products in specified international regions and Sharps became its exclusive distributor in the Americas. The Nephron distribution agreement was terminated; a logistics arrangement with Owens & Minor was being negotiated for a planned third-quarter 2024 start.
- Listing risk: Nasdaq granted an additional compliance period through July 8, 2024 to address the minimum-bid-price deficiency. The company said it may use a reverse stock split; there is no assurance it will regain compliance.
- Other risks: The company has no established operating revenue, needs additional capital, faces commercialization and manufacturing execution risks, competition, regulatory requirements, product-liability exposure, and potential shareholder dilution. Foreign-market approvals are not yet in place for its products, according to the filing.
- Auditor and controls: PKF O’Connor Davies issued an unqualified opinion on the 2023 financial statements while emphasizing going-concern uncertainty. The prior auditor resigned in December 2023, citing the company’s current and anticipated operations as outside its internal risk-tolerance metrics; the filing reports no disagreements. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not provide an internal-control opinion.
Important facts for investors to verify
- Confirm that this Sharps Technology filing, rather than a Skyai filing, is the intended document.
- Check subsequent cash burn, financing availability, and whether the company can fund operations and meet the going-concern challenge.
- Verify whether the disclosed South American purchase order converted into delivered product, recognized revenue, and collected cash.
- Track financing and closing progress for the Nephron facility asset purchase, plus actual timing for prefillable-syringe production.
- Confirm implementation of distribution and logistics arrangements, and monitor order volume and customer demand.
- Monitor Nasdaq bid-price compliance and any reverse-stock-split action, as well as potential dilution from outstanding warrants and options.